Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hepatocellular carcinoma
Josep M. Llovet, Robin Kate Kelley, Augusto Villanueva, et al.
Nature Reviews Disease Primers (2021) Vol. 7, Iss. 1
Open Access | Times Cited: 4406

Showing 1-25 of 4406 citing articles:

Hepatocellular carcinoma
Arndt Vogel, Tim Meyer, Gonzalo Sapisochín, et al.
The Lancet (2022) Vol. 400, Iss. 10360, pp. 1345-1362
Closed Access | Times Cited: 1316
Immunotherapies for hepatocellular carcinoma
Josep M. Llovet, Florian Castet, Mathias Heikenwälder, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 3, pp. 151-172
Closed Access | Times Cited: 1159
Liver cirrhosis
Pere Ginès, Aleksander Krag, Juan G. Abraldeṣ, et al.
The Lancet (2021) Vol. 398, Iss. 10308, pp. 1359-1376
Closed Access | Times Cited: 942
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol, et al.
Nature (2021) Vol. 592, Iss. 7854, pp. 450-456
Open Access | Times Cited: 925
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
Amit G. Singal, Josep M. Llovet, Mark Yarchoan, et al.
Hepatology (2023) Vol. 78, Iss. 6, pp. 1922-1965
Open Access | Times Cited: 686
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Dandan Peng, Minyang Fu, Manni Wang, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 553
Evolving therapeutic landscape of advanced hepatocellular carcinoma
Chen Yang, Hailin Zhang, Linmeng Zhang, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 20, Iss. 4, pp. 203-222
Closed Access | Times Cited: 417
The immunological and metabolic landscape in primary and metastatic liver cancer
Xin Li, Pierluigi Ramadori, Dominik Pfister, et al.
Nature reviews. Cancer (2021) Vol. 21, Iss. 9, pp. 541-557
Closed Access | Times Cited: 395
Role of pyroptosis in inflammation and cancer
Wei Xiang, Feng Xie, Xiaoxue Zhou, et al.
Cellular and Molecular Immunology (2022) Vol. 19, Iss. 9, pp. 971-992
Open Access | Times Cited: 391
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial
Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 8, pp. 995-1008
Open Access | Times Cited: 386
Hypoxia-inducible factors: cancer progression and clinical translation
Elizabeth E. Wicks, Gregg L. Semenza
Journal of Clinical Investigation (2022) Vol. 132, Iss. 11
Open Access | Times Cited: 337
Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review
Kyoko Oura, Asahiro Morishita, Joji Tani, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 11, pp. 5801-5801
Open Access | Times Cited: 306
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Amit G. Singal, Fasiha Kanwal, Josep M. Llovet
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 12, pp. 864-884
Closed Access | Times Cited: 300
Molecular pathogenesis and systemic therapies for hepatocellular carcinoma
Josep M. Llovet, Roser Pinyol, Robin Kate Kelley, et al.
Nature Cancer (2022) Vol. 3, Iss. 4, pp. 386-401
Open Access | Times Cited: 272
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis
Amit G. Singal, Emily Zhang, Manasa Narasimman, et al.
Journal of Hepatology (2022) Vol. 77, Iss. 1, pp. 128-139
Open Access | Times Cited: 250
Deuterium in drug discovery: progress, opportunities and challenges
Rita Maria Concetta Di Martino, Brad D. Maxwell, Tracey Pirali
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 562-584
Open Access | Times Cited: 234
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Shukui Qin, Minshan Chen, Ann‐Lii Cheng, et al.
The Lancet (2023) Vol. 402, Iss. 10415, pp. 1835-1847
Closed Access | Times Cited: 234
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis
Darren Jun Hao Tan, Cheng Han Ng, Snow Yunni Lin, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 4, pp. 521-530
Open Access | Times Cited: 215
Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma
Philip J. Johnson, Qing Zhou, Doan Y Dao, et al.
Nature Reviews Gastroenterology & Hepatology (2022) Vol. 19, Iss. 10, pp. 670-681
Closed Access | Times Cited: 204
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
Adithya Chennamadhavuni, Laith Abushahin, Ning Jin, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 203
NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options
Friedrich Foerster, Simon Johannes Gairing, Lukáš Müller, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 446-457
Open Access | Times Cited: 196
Lipid alterations in chronic liver disease and liver cancer
Bichitra Paul, Monika Lewińska, Jesper B. Andersen
JHEP Reports (2022) Vol. 4, Iss. 6, pp. 100479-100479
Open Access | Times Cited: 196
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 195
A targetable LIFR−NF-κB−LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis
Fan Yao, Yalan Deng, Yang Zhao, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 194
Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers
Jinzhu Mao, Dongxu Wang, Junyu Long, et al.
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 12, pp. e003334-e003334
Open Access | Times Cited: 185
Page 1 - Next Page

Scroll to top